Sun Pharmaceutical Industries Ltd. NSE: SUNPHARMA | BSE: 524715

Mid-range Performer

Download real time

1648.60 28.40 (1.75%)

1.9M

NSE+BSE Volume

NSE 18 Sep, 2025 3:59 PM (IST)

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2050.25. The consensus estimate represents an upside of 24.36% from the last price of 1648.60. View 14 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	18 Sep 2025	Sun Pharmaceutical	Consensus Share Price Target	1648.60	1928.71	-	16.99	buy	pdf Detailed Estimates
	13 Jun 2022	Sun Pharmaceutical	Geojit BNP Paribas Target	1648.60	970.00	793.40 (107.79%)	Target met	Buy	pdf post cache		Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Sun Pharmaceutical	Prabhudas Lilladhar Target	1648.60	1020.00	859.55 (91.80%)	Target met	Buy	pdf post cache		Broker Report SUN PHARMACEUTICAL I Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Sun Pharmaceutical	Motilal Oswal Target	1648.60	1040.00	860.60 (91.56%)	Target met	Buy	pdf post cache		Broker Report India/US drives while RoW/EMs drags 4QFY22 performance Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1648.60	1100.00	839.25 (96.44%)		Buy	pdf post cache		Broker Report Sun Pharma (BUY): Strong India growth; cost normalisation impacts margins BOB Capital Markets Ltd. Q4 EBITDA/adj. PAT declined 17%/28% QoQ (+6%/-5% YoY) due to 350bps QoQ contraction in operating margin pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Sun Pharmaceutical	ICICI Direct	1648.60	1070.00	839.25 (96.44%)	Target met	Buy	pdf post cache		Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1648.60	961.00	888.30 (85.59%)	Target met	Accumulate	pdf post cache		Broker Report US speciality, domestic businesses drive Q4 ICICI Securities Limited Sun Pharmaceutical’s (Sun) reported Q4FY22 performance was marginally lower than our estimates. Consolidated revenue grew 10.8% YoY to Rs94.5bn (and adj. PAT was up 17.8% to Rs15.8bn. EBITDA margin was 24.8% against our estimate of 25.6%. Specialty portfolio grew 1.6% QoQ to US$186mn versus our estimate of US$185mn led by growth in Ilumya, Cequa and Odomzo, largely offset by increased generic completion in Absorica. pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Sun Pharmaceutical	SMC online	1648.60		865.10 (90.57%)		Results Update	pdf post cache		Broker Report Sun Pharmaceutical Industries SMC online pdf Copy Link Share on Share on Share on Share on Alert
	24 Feb 2022	Sun Pharmaceutical	BOB Capital Markets Ltd.	1648.60	1045.00	831.55 (98.26%)	Target met	Buy	pdf post cache		Broker Report Sun Pharma (BUY): Alchemee acquisition to expand global branded derma portfolio BOB Capital Markets Ltd. SUNP, through subsidiary Taro Pharma, to acquire Galderma's skincare arm Alchemee in US$ 90mn all-cash deal pdf Copy Link Share on Share on Share on Share on Alert
	02 Feb 2022	Sun Pharmaceutical	ICICI Securities Limited Target	1648.60	1075.00	890.65 (85.10%)		Buy	pdf post cache		Broker Report Sun Pharma ICICI Securities Limited pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2022	Sun Pharmaceutical	Prabhudas Lilladhar Target	1648.60	1050.00	883.55 (86.59%)	Target met	Buy	pdf post cache		Broker Report SUN PHARMACEUTICAL I Prabhudas Lilladhar Other expenses inch up QoQ and YoY led by normalization of expenses. growth of +12% YoY aided by 1) specialty ramp-up across the globe, 2) focus significant investments and efforts in specialty business has started paying off in upward trajectory of revenue. Sustained momentum in specialty will help in improving operating leverage and margins. Also, domestic... pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners